We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
PTC Therapeutics (PTCT) Moves 7.2% Higher: Will This Strength Last?
Read MoreHide Full Article
PTC Therapeutics (PTCT - Free Report) shares ended the last trading session 7.2% higher at $78.53. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 4.2% gain over the past four weeks.
Last month, the company reported robust financial results for the first quarter of 2026. The growing investor confidence related to PTC Therapeutics’ marketed product Sephience (sepiapterin), which is approved for the treatment of phenylketonuria (PKU) and continues to see a strong launch, might have driven the recent share price rally.
This biopharmaceutical company is expected to post quarterly earnings of $0.11 per share in its upcoming report, which represents a year-over-year change of +113.3%. Revenues are expected to be $297.27 million, up 66.2% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For PTC Therapeutics, the consensus EPS estimate for the quarter has been revised 156% higher over the last 30 days to the current level. And a positive trend in earnings estimate revision usually translates into price appreciation. So, make sure to keep an eye on PTCT going forward to see if this recent jump can turn into more strength down the road.
PTC Therapeutics belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, BioNTech SE Sponsored ADR (BNTX - Free Report) , closed the last trading session 3% higher at $92.22. Over the past month, BNTX has returned 2%.
BioNTech's consensus EPS estimate for the upcoming report has changed +0.3% over the past month to -$2.44. Compared to the company's year-ago EPS, this represents a change of -34.1%. BioNTech currently boasts a Zacks Rank of #3 (Hold).
View the Zacks #1 Rank List
Image: Bigstock
PTC Therapeutics (PTCT) Moves 7.2% Higher: Will This Strength Last?
PTC Therapeutics (PTCT - Free Report) shares ended the last trading session 7.2% higher at $78.53. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 4.2% gain over the past four weeks.
Last month, the company reported robust financial results for the first quarter of 2026. The growing investor confidence related to PTC Therapeutics’ marketed product Sephience (sepiapterin), which is approved for the treatment of phenylketonuria (PKU) and continues to see a strong launch, might have driven the recent share price rally.
This biopharmaceutical company is expected to post quarterly earnings of $0.11 per share in its upcoming report, which represents a year-over-year change of +113.3%. Revenues are expected to be $297.27 million, up 66.2% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For PTC Therapeutics, the consensus EPS estimate for the quarter has been revised 156% higher over the last 30 days to the current level. And a positive trend in earnings estimate revision usually translates into price appreciation. So, make sure to keep an eye on PTCT going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
PTC Therapeutics belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, BioNTech SE Sponsored ADR (BNTX - Free Report) , closed the last trading session 3% higher at $92.22. Over the past month, BNTX has returned 2%.
BioNTech's consensus EPS estimate for the upcoming report has changed +0.3% over the past month to -$2.44. Compared to the company's year-ago EPS, this represents a change of -34.1%. BioNTech currently boasts a Zacks Rank of #3 (Hold).